Our adoptive cell transfer therapy with tumor-infiltrating lymphocytes involves the extraction of immune cells that have penetrated the tumor, which are then grown in large numbers in the laboratory before being reintroduced into the patient. This innovative approach has shown promising results in clinical trials, offering a potential lifeline for patients with advanced stage cancers that are resistant to traditional treatments, At Beijing BIOOCUS Biotech Ltd., we are committed to revolutionizing cancer treatment through cutting-edge research and development. With our adoptive cell transfer therapy, we aim to provide a safer and more effective alternative to traditional cancer treatments, ultimately improving patient outcomes and quality of life. Join us in the fight against cancer and explore the potential of adoptive cell transfer therapy with tumor-infiltrating lymphocytes
Please feel free to give your inquiry in the form below We will reply you in 24 hours